Hauser SL, Cree BAC (2020) Treatment of multiple sclerosis: a review. Am J Med 133:1380-1390.e2. https://doi.org/10.1016/j.amjmed.2020.05.049
Article CAS PubMed PubMed Central Google Scholar
Walton C, King R, Rechtman L, et al (2020) Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler J 26:1816–1821. https://doi.org/10.1177/1352458520970841
Fukaura H (2014) Disease modifying therapies in multiple sclerosis. Nihon Rinsho 72:2015–2022. https://doi.org/10.1155/2014/307064
Thomas FP (2012) Multiple sclerosis. Pathy’s Princ Pract Geriatr Med Fifth Ed 37:175–184. https://doi.org/10.1002/9781119952930.ch70
Vattathara JJ, Prakash O, Subhramanian S et al (2020) Substrate specific inhibitor designed against the immunomodulator GMF-beta reversed the experimental autoimmune encephalomyelitis. Sci Rep 10:1–13. https://doi.org/10.1038/s41598-020-60710-2
De Angelis F, John NA, Brownlee WJ (2018) Disease-modifying therapies for multiple sclerosis. BMJ 363:1–10. https://doi.org/10.1136/bmj.k4674
Cunniffe N, Coles A (2021) Promoting remyelination in multiple sclerosis. J Neurol 268:30–44. https://doi.org/10.1007/s00415-019-09421-x
Metaxakis A, D. Petratou NT, (2020) Molecular interventions towards multiple sclerosis treatment. Brain Sci 10:1–20. https://doi.org/10.1038/219436a0
Münzel EJ, Williams A (2013) Promoting remyelination in multiple sclerosis-recent advances. Drugs 73:2017–2029. https://doi.org/10.1007/s40265-013-0146-8
Article CAS PubMed Google Scholar
Göttle P, Förster M, Weyers V et al (2019) An unmet clinical need: roads to remyelination in MS. Neurol Res Pract 1:1–12. https://doi.org/10.1186/s42466-019-0026-0
Gacem N, Nait-Oumesmar B (2021) Oligodendrocyte development and regenerative therapeutics in multiple sclerosis. Life 11:1–15. https://doi.org/10.3390/life11040327
Huang JK, Fancy SPJ, Zhao C et al (2011) Myelin regeneration in multiple sclerosis: targeting endogenous stem cells. Neurotherapeutics 8:650–658. https://doi.org/10.1007/s13311-011-0065-x
Article PubMed PubMed Central Google Scholar
Justyna W (2017) Oligodendrocyte regeneration: its significance in myelin replacement and neuroprotection in multiple sclerosis. Physiol Behav 176:139–148. https://doi.org/10.1016/j.physbeh.2017.03.040
Mi S, Sandrock A, Miller RH (2008) LINGO-1 and its role in CNS repair. Int J Biochem Cell Biol 40:1971–1978. https://doi.org/10.1016/j.biocel.2008.03.018
Article CAS PubMed Google Scholar
Hanafy KA, Sloane JA (2011) Regulation of remyelination in multiple sclerosis. FEBS Lett 585:3821–3828. https://doi.org/10.1016/j.febslet.2011.03.048
Article CAS PubMed Google Scholar
Cobret L, De Tauzia ML, Ferent J et al (2015) Targeting the cis-dimerization of LINGO-1 with low MW compounds affects its downstream signalling. Br J Pharmacol 172:841–856. https://doi.org/10.1111/bph.12945
Article CAS PubMed Google Scholar
Sadanandan P, Payne NL, Sun G et al (2022) Exploiting the preferential phagocytic uptake of nanoparticle-antigen conjugates for the effective treatment of autoimmunity. Nanomedicine Nanotechnology, Biol Med 40. https://doi.org/10.1016/j.nano.2021.102481
Foale S, Berry M, Logan A et al (2017) LINGO-1 and AMIGO3, potential therapeutic targets for neurological and dysmyelinating disorders? Neural Regen Res 12:1247–1251. https://doi.org/10.4103/1673-5374.213538
Article CAS PubMed PubMed Central Google Scholar
Rudick RA, Mi S, Sandrock AW (2008) LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert Opin Biol Ther 8:1561–1570. https://doi.org/10.1517/14712598.8.10.1561
Article CAS PubMed Google Scholar
Andrews JL, Fernandez-Enright F (2015) A decade from discovery to therapy: LINGO-1, the dark horse in neurological and psychiatric disorders. Neurosci Biobehav Rev 56:97–114. https://doi.org/10.1016/j.neubiorev.2015.06.009
Article CAS PubMed Google Scholar
Huang LJ, Li G, Ding Y, et al (2019) LINGO-1 deficiency promotes nerve regeneration through reduction of cell apoptosis, inflammation, and glial scar after spinal cord injury in mice. Exp Neurol 320:. https://doi.org/10.1016/j.expneurol.2019.112965
Ruggieri S, Tortorella C, Gasperini C (2017) Anti LINGO 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis. Expert Rev Neurother 17:1081–1089. https://doi.org/10.1080/14737175.2017.1378098
Article CAS PubMed Google Scholar
Hanf KJM, Arndt JW, Liu YT, et al (2020) Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding site. MAbs 12:. https://doi.org/10.1080/19420862.2020.1713648
Cadavid D, Mellion M, Hupperts R et al (2019) Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 18:845–856. https://doi.org/10.1016/S1474-4422(19)30137-1
Article CAS PubMed Google Scholar
Ahmed SMU, Luo L, Namani A et al (2017) Nrf2 signaling pathway: pivotal roles in inflammation. Biochim Biophys Acta - Mol Basis Dis 1863:585–597
Article CAS PubMed Google Scholar
Wu T, Mohan C (2009) The AKT axis as a therapeutic target in autoimmune diseases. Endocrine, Metab Immune Disord - Drug Targets 9:145–150. https://doi.org/10.2174/187153009788452417
Bothwell M (2017) Mechanisms and medicines for remyelination. Annu Rev Med 68:431–443. https://doi.org/10.1146/annurev-med-050715-104400
Article CAS PubMed Google Scholar
Russo C Dello, Navarra P, Lisi L (2016) mTOR in multiple sclerosis : the emerging role in the regulation of glial biology. Elsevier Inc.
Gaesser JM, Fyffe-Maricich SL (2016) Intracellular signaling pathway regulation of myelination and remyelination in the CNS. Exp Neurol 283:501–511. https://doi.org/10.1016/j.expneurol.2016.03.008
Article CAS PubMed PubMed Central Google Scholar
Wei X, Luo L, Chen J (2019) Roles of mTOR signaling in tissue regeneration. Cells 8:. https://doi.org/10.3390/cells8091075
Parmar N, Tamanoi F (2010) Rheb G-Proteins and the Activation of mTORC1. Enzymes 27:39–56. https://doi.org/10.1016/S1874-6047(10)27003-8. PMID: 25429186; PMCID: PMC4241847
Article CAS PubMed PubMed Central Google Scholar
Gouvêa-Junqueira D, Falvella ACB, Antunes ASLM et al (2020) Novel treatment strategies targeting myelin and oligodendrocyte dysfunction in schizophrenia. Front Psychiatry 11:1–16. https://doi.org/10.3389/fpsyt.2020.00379
Kumar S, Patel R, Moore S et al (2013) Estrogen receptor β ligand therapy activates PI3K/Akt/mTOR signaling in oligodendrocytes and promotes remyelination in a mouse model of multiple sclerosis. Neurobiol Dis 56:131–144. https://doi.org/10.1016/j.nbd.2013.04.005
Article CAS PubMed Google Scholar
Ornelas IM, Khandker L, Wahl SE et al (2020) The mechanistic target of rapamycin pathway downregulates bone morphogenetic protein signaling to promote oligodendrocyte differentiation. Glia 68:1274–1290. https://doi.org/10.1002/glia.23776
Article PubMed PubMed Central Google Scholar
Mammana S, Bramanti P, Mazzon E et al (2018) Oncotarget 8263 www.impactjournals.com/oncotarget Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis. Oncotarget 9:8263–8277
Article PubMed PubMed Central Google Scholar
Shao Q, Zhao M, Pei W et al (2021) Pinocembrin promotes OPC differentiation and remyelination via the mTOR signaling pathway. Neurosci Bull. https://doi.org/10.1007/s12264-021-00696-7
Article PubMed PubMed Central Google Scholar
Ehrenreich H, Stadelmann C (2004) Bähr1 M, Diem R, Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 11:S181–S192. https://doi.org/10.1038/sj.cdd.4401504
Article CAS PubMed Google Scholar
Podbielska M, Banik NL, Kurowska E, Hogan EL (2013) Myelin recovery in multiple sclerosis: the challenge of remyelination. Brain Sci 3:1282–1324. https://doi.org/10.3390/brainsci3031282
Article CAS PubMed PubMed Central Google Scholar
Aparicio E, Mathieu P, Luppi MP et al (2013) The notch signaling pathway: its role in focal CNS demyelination and apotransferrin-induced remyelination. J Neurochem 127:819–836. https://doi.org/10.1111/jnc.12440
Article CAS PubMed Google Scholar
D’Souza B, Miyamoto A, Weinmaster G (2008) The many facets of Notch ligands. Oncogene 27:5148–5167. https://doi.org/10.1038/onc.2008.229
Article CAS PubMed PubMed Central Google Scholar
Kopan R, Ilagan MXG (2009) The canonical notch signaling pathway: unfolding the activation mechanism. Cell 137:216–233. https://doi.org/10.1016/j.cell.2009.03.045
Article CAS PubMed PubMed Central Google Scholar
Bassil R, Orent W, Elyaman W (2013) Notch signaling and t-helper cells in EAE/MS. Clin Dev Immunol 2013:. https://doi.org/10.1155/2013/570731
Mathieu P, Adami PVM, Morelli L (2013) Notch signaling in the pathologic adult brain. Biomol Concepts 4:465–476. https://doi.org/10.1515/bmc-2013-0006
留言 (0)